MetaCap

CalciMedica Inc. (CALC)

NASDAQ: CALCHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.26+0.09 (+7.69%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CALC stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$4.41
52-week range
1.00 – 36.00
Day range
1.20 – 1.33
Volume / Avg
86.25K / 80.15K
Beta
—

52-week range

$1.00$36.00

CALC stock today

CalciMedica (CALC) closed at $1.26 on Nov 20, up 7.69% (+$0.09), versus the S&P 500's 3.70% decline. Shares are 96.5% below their 52-week high of $36.00, set on Dec 26, 2025 and 26.0% above the 52-week low of $1.00, near the bottom of the past year's range. CALC is down 96.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 92.3%.

CalciMedica has posted a net loss over the last twelve months (EPS of -$4.41), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About CalciMedica

Company profile

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. A. Rachel Leheny Ph.D.
Headquarters
La Jolla, CA
Employees
15
IPO year
2023

Financial highlights

Full financials

CalciMedica reported a net loss of $29.6 million, compared with a loss of $13.7 million a year earlier. Diluted earnings per share came in at -$1.97.

CalciMedica annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-29.56M$-13.70M$-34.36M$-7.82M$-35.82M
EPS (diluted)$-1.97$-1.22$-7.66$-111.16$-1.69

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$50.00+3868.25%

  • Strong buy 0
  • Buy 3
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $30.00High $75.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.24 vs $-0.75
Surprise
+68.00%

CALC news

All CALC news

CalciMedica peers

Health Care sector
CALC peer companies
CompanyPrice% ChgMarket capCompare
OPTHOptimi Health Corp.1.51-13.71%$8.65Mvs CALC
BIVIBioVie Inc. Class A0.80-12.07%$8.58Mvs CALC
LEXXLexaria Bioscience Corp.4.03-10.24%$8.49Mvs CALC
HINDVyome Holdings Inc.1.20-17.24%$8.42Mvs CALC
GDTCCytoMed Therapeutics Limited0.755-2.33%$9.01Mvs CALC
QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares1.29-9.15%$8.29Mvs CALC
MBRXMoleculin Biotech Inc.7.74-2.40%$8.22Mvs CALC
PTNPalatin Technologies Inc.4.58-7.10%$8.16Mvs CALC

Indexes, lists and sector

CalciMedica stock FAQ

What is CalciMedica's stock price today?

CALC last traded at $1.26 as of Nov 20, 4:00 PM EST, up 7.69% on the day. Prices are delayed at least 15 minutes.

Does CalciMedica pay a dividend?

No. CalciMedica does not currently pay a regular cash dividend.

Who is CalciMedica's CEO?

Dr. A. Rachel Leheny Ph.D. is the chief executive officer of CalciMedica Inc., which has about 15 employees.

Has CALC ever split its stock?

Yes. The most recent CALC stock split was a 1-for-5 split on Aug 31, 2026.

What is the CALC 52-week high?

The 52-week high for CALC is $36.00 and the 52-week low is $1.00. The stock is currently 96.5% below its high.

Compare CALC